

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

| Drug class | Platform | Product candidate | Indication (target) | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | BioNTech rights ¹ | Collaborator/ Partner |
|-----------------------------------|--|---|--|--------------------------|-------------|---------|---------|------------------------------|------------------------|
| mRNA | FixVac | BNT111 | Advanced, R/R melanoma | | | | | | |
| | | BNT113 | Metastatic/ R/R HPV16+ head and neck cancer | | | | | Fully owned ² | |
| | | BNT116 | 1L metastatic NSCLC Advanced/metastatic NSCLC | rully owned ² | | | | | |
| | iNeST | BNT122 (autogene cevumeran) | 1L advanced melanoma Adjuvant colorectal cancer Adjuvant pancreatic ductal adenocarcinoma Multiple solid tumors | | | | | Collaboration | Genentech ³ |
| | RiboMabs | BNT142 | Multiple solid tumors (CD3×CLDN6) | | - | | | Fully owned | |
| | RiboCytokines | BNT151 | Multiple solid tumors (IL-2 variant) | | | | l | Fully owned | |
| | | BNT152 + BNT153 | Multiple solid tumors (IL-7, IL-2) | | <u> </u> | | i | | |
| therables | CAR T cells + CARVac | BNT211 | Multiple solid tumors (CLDN6) | | i — | · ——— | | Fully owned | |
| | Neoantigen-based T cells | BNT221 | Refractory metastatic melanoma | | I I | l | | Fully owned | |
| Protein- based therapeutics | Next-generation immune checkpoint modulators | BNT311 / GEN1046 (acasunlimab) BNT312 / GEN1042 | aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB) 2L endometrial cancer (PD-L1×4-1BB) Multiple solid tumors (PD-L1×4-1BB) Multiple solid tumors (CD40×4-1BB) ⁴ | | | | | Collaboration | Genmab |
| | | BNT313 / GEN1053 BNT314 / GEN1059 | Multiple solid tumors (CD27) Multiple solid tumors (EpCAM×4-1BB) | | | | | | |
| | | BNT322 / GEN1056 BNT316 / ONC-392 (gotistobart) | Multiple solid tumors aPD(L)1-R/R metastatic NSCLC (CTLA-4) Platinum-resistant ovarian cancer (CTLA-4) Metastatic castration-resistant prostate cancer (CTLA-4) Multiple solid tumors (CTLA-4) | | | | | Collaboration | OncoC4 |
| | Targeted cancer antibodies | BNT321 | Pancreatic cancer (sLea) | | i ! ! | | | Fully owned | |
| | Antibody-drug conjugates | BNT323 / DB-1303 | Multiple solid tumors (HER2) 2L+, HR+/HER2-low metastatic breast cancer (HER2) | | | | | Collaboration | Duality Bio |
| | | BNT324 / DB-1311 | Multiple solid tumors (B7H3) | | | | | , | |
| | | BNT325 / DB-1305 | Multiple solid tumors (TROP2) | | | | | | |
| SMI ⁵ | Toll-like receptor binding | BNT411 | Multiple solid tumors (TLR7) | | | | - | Fully owned | |



We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Infectious Diseases

| Drug class | Product candidate | Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 3 | Commercial | I I BioNTech rights | Collaborator/ Partner |
|------------|--|----------------------------------|---------|-----------|---------|---------|-------------|------------------------------|---|
| mRNA | COMIRNATY (BNT162b2) COMIRNATY+BNT162b4 (T-cell enhancing) | COVID-19 | | | | | | I I I Collaboration | Pfizer |
| | BNT162b5/6/7 (Stabilized spike antigen) | | | I | | | I I I | | Fosun Pharma |
| | COMIRNATY+BNT1616 | COVID-19 – Influenza combination | | | | | i I | Collaboration | Pfizer |
| | BNT161 | Influenza | | | | | | Collaboration | Pfizer |
| | BNT163 | HSV | | | | | i I I | Collaboration | University of Pennsylvania |
| | BNT164 | Tuberculosis | | | | | | Fully owned | Funded by Bill & Melinda Gates Foundation |
| | BNT165 | Malaria | | | | | <u> </u> | Fully owned | |
| | BNT166 | Мрох | | | i | i | | Fully owned | Funded by CEPI7 |
| | BNT167 | Shingles | | <u> </u> | : | : | i | Collaboration | Pfizer |

¹ For further details about BioNTech's rights see quarterly reports under https://investors.biontech.de/financials-filings/quarterly-reports.

² FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

³ A member of the Roche group.

⁴ Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy.

⁵ Small molecule immunomodulators.

⁶ The COVID-19-Influenza combination is a Phase 1/2 trial in partnership with Pfizer. Further development is subject to entering into a definitive agreement.

⁷ Coalition for Epidemic Preparedness Innovations (CEPI).